Physician profile
Gary A Moore
NPI 1306888300
$283.36
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $119 · 2020: $74.24 · 2021: $74.78 · 2022: $15.10.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $57.36 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $40.34 | 2019-2022 | |
| Abbvie INC. | $30.00 | 2020 | |
| Merck Sharp & Dohme LLC | $27.46 | 2020-2021 | |
| Amgen INC. | $26.36 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.18 | 2021 | |
| Amarin Pharma, INC. | $22.12 | 2019 | |
| Xeris Pharmaceuticals, INC. | $20.00 | 2021 | |
| Janssen Pharmaceuticals, INC | $18.01 | 2019 | |
| Novo Nordisk INC | $17.53 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.